Packages of care for schizophrenia in low- and middle-income countries. by de Jesus, Mari Jair et al.
1
Neglected Diseases
Packages of Care for Schizophrenia in Low- and Middle-
Income Countries
Jair de Jesus Mari1,2*, Denise Razzouk1, Rangaswamy Thara3, Julian Eaton4, Graham Thornicroft2
1Department of Psychiatry, Universidade Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil, 2Health Services and Population Research Department, Institute of Psychiatry, King’s
London, United Kingdom, 3 Schizophrenia Research Foundation, Chennai, India, 4CBM International, West Africa Region, Abuja, Nigeria
This is the third in a series of articles highlighting the delivery of
‘‘packages of care’’ for mental health disorders in low- and middle-
income countries. Packages of care are combinations of treatments aimed
at improving the recognition and management of conditions to achieve
optimal outcomes.
Introduction
The schizophrenia syndrome, a relatively rare mental disorder,
comprises thought disorder, unusual beliefs (delusions), misper-
ceptions (mainly auditory hallucinations), cognitive and affective
symptoms, and negative symptoms such as blunted affect, lack of
motivation, and an experience of emptiness. The first episode of
schizophrenia, which usually occurs when patients are in their
early twenties, may have an abrupt or insidious onset. Introspec-
tion, defensiveness, and eccentricity can be part of the premorbid
personality. Before the onset of psychotic symptoms, social
performance and interpersonal relationships can be altered or
near to normal. Box 1 shows the International Classification of
Disease (ICD) 10 diagnostic criteria for schizophrenia [1].
The incidence and prevalence of schizophrenia vary substan-
tially across sites, with a higher incidence and prevalence among
males, migrants, and those living in urban environments [2–4].
Worldwide, the median incidence of schizophrenia is around 1.5
per 10,000 inhabitants [2], and the lifetime morbid risk of
developing schizophrenia is near 0.7% [3]. The incidence ratio for
men to develop schizophrenia relative to women is 1.42 [5].
People with schizophrenia have a 2–3-fold higher mortality rate
than the general population, a differential gap that has increased
over recent decades [4,6] and that now amounts to an average loss
of 25–30 y of potential life among people with schizophrenia [7,8].
There are several reasons for this differential mortality gap.
Patients with schizophrenia have an increased prevalence of
metabolic syndrome and its components, which are risk factors for
cardiovascular disease and type 2 diabetes [7]. They also have
higher rates of smoking and reduced physical activity than the
general population. Furthermore, a 10-y longitudinal study in
China showed that both the all-cause mortality rate and the
suicide rate were higher among men with schizophrenia than
among women with the disorder [9]. In general, 28% of the excess
mortality associated with schizophrenia is attributable to suicide
and 12% to accidents [10]. Finally, social factors such as poverty
and reduced access to medical care and the adverse metabolic side
effects associated with psychotropic treatments combine to
increase the risk of cardiovascular diseases, metabolic syndrome,
and sudden deaths among people with schizophrenia [8].
Although the incidence of schizophrenia is low, its early onset,
long duration, and severe disability make it a leading contributor
to the burden of disease in developing countries [11]. Many low-
and middle-income countries (LMICs) have fewer than one
psychiatrist per 100,000 population (Table S1). Throughout most
of Africa, Melanesia, and Polynesia there is inadequate personnel
to treat mental disorders. In particular, there is a scarcity of
psychiatric nurses [12]. This lack of human resources is a major
contributor to a worldwide treatment gap for schizophrenia
[13,14]. It is estimated that around 41.7 million people with
schizophrenia are in need of care in LMICs (Table S1), a worrying
statistic given that a delay in treatment of psychosis in LMICs is
highly associated with poor outcomes and increasing levels of
disabilities [15,16].
In this article, we focus on the effective management of
schizophrenia in LMICs. We review the available evidence on the
efficacy of treatments and delivery of care strategies in LMICs.
Because this evidence is limited, we also consider evidence from
systematic reviews, meta-analyses, and key trials from high-income
countries (HICs). On the basis of our review, we propose a
package of care—a combination of treatments designed to
improve the recognition and management of conditions to achieve
optimal outcomes—for schizophrenia.
The Evidence on the Treatment of Schizophrenia
Detection of Schizophrenia
A necessary preliminary stage to assist people with a recent
onset of schizophrenia is case finding [17]. Detection at the
prodromal stage is at present ethically problematic, for example, in
relation to providing medication to the proportion of at-risk cases
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who will not develop the condition [18]. Nevertheless, in America,
Europe, and Australasia, the use of specialized early intervention
teams, which aim to prevent or delay the transition to a psychotic
disorder by identifying individuals with subthreshold symptoms at
high risk of developing psychosis [19,20], is now well established,
although with conflicting results [21–23].
Where case finding is directed towards identifying individuals
who have already ‘‘converted’’ from the prodromal stage to meet
the diagnostic criteria for schizophrenia, there is emerging
evidence from HICs that reducing the duration of untreated
psychosis can benefit patients. The number of relapses may be
reduced [24], the long-term clinical outcome may be improved
[25], and suicide rates may fall [26]. Nevertheless, despite a
consensus about the potential public-health benefits of the early
detection of schizophrenia [27], there is signal lack of evidence for
such benefits in LMICs. Furthermore, there is an ongoing debate
about whether the long-term course and outcome of schizophrenia
is more benign in low-income settings than in HICs [28,29].
In one project in Nigeria, village health workers were
specifically trained in the recognition of severe mental illness.
These workers, who were based in primary care clinics and who
had responsibility for case finding in nearby villages, increased the
referral rates for cases of schizophrenia [30]. In another program
in rural India, community-based rehabilitation workers who were
trained to recognize schizophrenia identified and enrolled most of
the untreated patients into the program [31,32].
Pharmacotherapy
Psychotic conditions can be treated with first-generation
antipsychotics (FGAs) such as haloperidol and chlorpromazine or
with second-generation antipsychotics (SGAs) such as clozapine and
olanzapine. Antipsychotics are generally high-affinity antagonists of
dopamine D2 receptors. In LMICs, the usual drug treatment for
schizophrenia is an FGA. Evidence from trials undertaken in both
HICs [33–35] and in China, an LMIC [36], indicates that FGAs are
as effective as SGAs for the treatment of the first episode of
schizophrenia (Table 1). Meta-analyses that considered evidence
collected in HICs indicate that oral haloperidol and chlorpromazine
are more effective than placebo [37–39], and as effective as the
newer antipsychotic compounds in the treatment of the main
psychotic symptoms (delusions and auditory hallucinations) of
schizophrenia [33,40,41]. However, in a naturalistic trial in Brazil
olanzapine had advantages over FGAs in terms of improving
negative symptoms and quality of life and reducing the incidence of
tardive dyskinesia [42,43]. Finally, a recent meta-analysis of
evidence collected in HICs showed that four SGAs (amisulpride,
clozapine, olanzapine, and risperidone) were superior to FGAs [44].
For agitated patients, evidence collected in HICs [45] and
LMICs [46,47] indicates that the combination of haloperidol and
promethazine can effectively control disturbed behavior.
Box 1. International Classification of Diseases
10 Criteria for Schizophrenia
One of symptoms (a–d), or two of symptoms (e–i) should
be present for most days in the past month.
(a) Thought echo, thought insertion or withdrawal, and
thought broadcasting;
(b) Delusions of control, influence, or passivity, clearly
referred to body or limb movements or specific
thoughts, actions, or sensations; delusional perception;
(c) Hallucinatory voices giving a running commentary
on the patient’s behaviour, or discussing the patient
among themselves, or other types of hallucinatory
voices coming from some part of the body;
(d) Persistent delusions of other kinds that are culturally
inappropriate and completely impossible, such as
religious or political identity, or superhuman powers
and abilities (e.g. being able to control the weather,
or being in communication with aliens from another
world);
(e) Persistent hallucinations in any modality, when
accompanied either by fleeting or half-formed
delusions without clear affective content, or by
persistent over-valued ideas, or when occurring
every day for weeks or months on end;
(f) Breaks or interpolations in the train of thought, resulting
in incoherence or irrelevant speech, or neologisms;
(g) Catatonic behaviour, such as excitement, posturing,
or waxy flexibility, negativism, mutism, and stupor;
(h) ‘‘Negative’’ symptoms such as marked apathy, paucity
of speech, and blunting or incongruity of emotional
responses, usually resulting in social withdrawal and
lowering of social performance; it must be clear that
these are not due to depression or to medication;
(i) A significant and consistent change in the overall
quality of some aspects of personal behaviour,
manifest as loss of interest, aimlessness, idleness, a
self-absorbed attitude, and social withdrawal.
These symptoms are shared by most major classification
systems, with some differences in duration of illness, or
boundaries of subtypes of disorders.
Source: World Health Organization 1992 [1].
Summary Points
N It is estimated that about 41.7 million people need
treatment for schizophrenia and related disorders in low-
and middle-income countries (LMICs). The majority of these
cases are concentrated in Asia (70%) and Africa (16%).
N In countries with low resources, general physicians and
primary health care workers can be trained to recognise
and treat people with psychotic disorders in the
community. Health systems can scale up such interven-
tions across all routine-care settings by training general
physicians and primary health care workers to recognise
and treat clients with schizophrenia with effective,
evidence-based interventions.
N First- and second-generation antipsychotics (FGAs and
SGAs) are similarly effective in the acute treatment of
psychotic symptoms. In addition, a number of trials have
shown the efficacy of psycho-educational strategies to
improve adherence to antipsychotics, to decrease relapse
and readmission rates, and to have a positive impact in
social functioning of family members and patients.
N A package of care combining low doses of conventional
antipsychotics along with brief and simple psycho-
educational interventions is recommended as an impor-
tant strategy to decrease the treatment gap for
schizophrenia in LMICs.
N The combination of FGAs and psycho-educational
interventions are more cost-effective than the use of
drugs alone.
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Some patients do not stabilise even after prolonged treatment
with an FGA. Sometimes, the use of another antipsychotic may be
effective but it is important to explore other causes of nonresponse
to treatment, such as nonadherence with the medication regimen,
social stressors, or concurrent use of alcohol and/or other drugs
before changing a patient’s drug regimen. Evidence from meta-
analyses of trials undertaken in HICs suggests that a long-acting
injectable FGA preparation (for example, depot fluphenazine
decanoate or fluphenazine enanthate) can be effective in the case
of noncompliance with an oral FGA regime [48,49].
Family Education and Psychosocial Interventions
The comprehensive management of schizophrenia includes
psychosocial interventions as well as the use of medication. Early
findings that a negative family environment (‘‘expressed emotion’’
that includes high levels of criticism, hostility, or overinvolvement)
was related to a poorer prognosis of schizophrenia [50] led to the
development of interventions designed to improve the family
environment [51]. Several of these strategies have now been
shown to enhance functioning in areas such as independent living,
relationships, and work. Family interventions targeted at people in
close contact with the patient decreased the level of negative
expressed emotions, improved compliance with treatment, and
averted relapse and hospital admission in two HIC-based meta-
analyses [52,53] and in a Hong Kong-based study that involved a
mutual support group delivered by a trained psychiatric nurse
[54,55].
Simpler and less expensive brief psycho-educational interven-
tions that increase knowledge, insight, and management of the
illness have also been tested in both HICs and LMICs [56–58].
Patients and family members are provided with support,
information about medication and the illness, and management
strategies, either in small groups or on a one-to-one basis. A meta-
analysis of studies undertaken in HICs [56] and two trials
undertaken in China [57,58] show that approaches of this type can
improve compliance, decrease relapse, and decrease readmission
Table 1. The evidence in support of schizophrenia treatment.
Schizophrenia Treatment Evidence from HICs Evidence from LMICs
Recognition of schizophrenia Meta-analysis of early intervention for psychosis [21] Two longitudinal studies in rural India [31,32]
Antipsychotic pharmacotherapy:
first episode
A meta-analysis and two RCTs comparing FGAs and
SGAs for the treatment of first psychotic episodes
[33–35]
RCT from China comparing the FGA haloperidol with the
SGA olanzapine for first episode [36]
Antipsychotic pharmacotherapy Meta-analyses of treatment with haloperidol and
chlorpromazine [37–39]
Naturalistic trial from Brazil comparing olanzapine with
FGAs in terms of effects on negative symptoms, quality of
life, and the incidence of tardive dyskinesia [42,43]
Meta-analyses of treatment with SGAs [39–41] —
Meta-analysis comparing SGAs with FGAs [44] —
Rapid tranquilization Meta-analysis of haloperidol plus promethazine for
the control of psychosis-induced aggression [45]
Pragmatic RCT in psychiatric emergency settings in India
of intra-muscular olanzapine versus intramuscular
haloperidol plus promethazine for rapid tranquillization
[46]
— Pragmatic RCT of intramuscular haloperidol versus
intramuscular haloperidol plus promethazine in Brazil [47]
Long-acting antipsychotics Meta-review of depot antipsychotic drugs [48] —
Meta-analysis of depot fluphenazine decanoate [49] —
Psychosocial family interventions Meta-analyses of family psychosocial interventions
[52,53]
Study of a mutual support group for families in Hong
Kong [54,55]
Psycho-education Meta-analysis of psycho-education [56] RCT of psycho-education in rural China (Xinjin Country,
Chengdu) [57]
— RCT of family education delivered by nurses in Beijing [58]
— RCT of group psycho-education delivered by paramedical
staff in Nigeria [59]
Adherence therapy — RCT of the efficacy of adherence therapy delivered by
nurses in Chiang Mai, Thailand [60]
Community based rehabilitation (CBR) — Two longitudinal studies of CBR in rural India [31,32]
Cognitive behavioral therapy (CBT) Meta-analysis of the effect of CBT on positive
symptoms [61]
—
RCTs of the effect of CBT on persistent psychotic
symptoms [62–65]
—
Promoting recovery-supportive
employment
Meta-analysis of vocational rehabilitation [67] —
Wellness training RCT of wellness training, health promotion for
severely mentally ill adults [66]
—
Assertive community treatment (ACT) Meta-analysis of the effects of ACT on time spent in
hospital and ability to live independently [68]
—
RCT, randomised controlled trial.
doi:10.1371/journal.pmed.1000165.t001
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rates. In addition, compliance with scheduled appointments
improved in a study in which four sessions of group psycho-
education were given to discharged patients in Nigeria by
paramedical staff [59].
Two additional psychosocial approaches have been tested in
LMICs. In a randomized controlled trial in Chiang Mai,
Thailand, eight sessions of adherence therapy (a behavioral
approach designed to enhance compliance with antipsychotic
medication) improved psychotic symptoms in patients after 9 wk
follow-up [60]. In two studies in rural India, a community-based
rehabilitation model in which mental-health workers helped
families and clients to recognise symptoms of the disease improved
treatment compliance, social inclusion, and social functioning
[31,32]. Additional resources for psychosocial intervention pack-
ages are provided in Table S2.
The efficacy of several other psychosocial interventions has been
tested only in HICs (Table 1). These include the use of individual
cognitive behavioral therapy to decrease positive and persistent
symptoms [61–64], and suicidal ideation [65], the use of wellness
training as health promotion [66], vocational rehabilitation [67],
and assertive community care (ACT), a strategy designed to
decrease time spent in hospital and to promote living indepen-
dence [68].
Delivery of Effective Interventions
The World Health Organization (WHO) ATLAS [69] clearly
shows the lack of adequate mental health services in many parts of
the world, especially in rural areas in LMICs. The best way to
tackle the treatment gap in LMICs is to take advantage of the
existing primary health care facilities [70] and to make efficient use
of the scarce specialised personnel to train nonspecialist health
professionals to identify and manage psychiatric disorders [71,72].
In India, for example, the training of community-level workers has
been shown to be an effective way to improve the detection of
schizophrenia and other major mental disorders and to improve
their treatment or referral to the appropriate centres of care
[31,32,73]. To improve access to treatment, providers of mental-
health services must make deliberate efforts to raise awareness
among communities [74] about the treatability of mental illness
and about how to access services. They must also endeavour to
reduce the stigma and discrimination associated with mental
illness. A recent study suggests that the most effective interventions
to achieve this aim are direct social contact with people with
mental illness at the individual level and the promotion of social
marketing (advertising and promotional methods designed to
achieve a social good rather than sales of a commodity) at the
population level [75].
In Table 2 and the rest of this section, we describe a series of
steps or strategies that might be used to deliver care for
schizophrenia in LMICs.
Interventions to Increase Demand for Care Packages
One important aspect of delivering schizophrenia care in LMICs is
to ensure that the strategy adopted is tailored to local circumstances.
Several trials in LMICs have shown the feasibility of training primary
health care workers to undertake psycho-educational activities
[54,55,57–60] that are driven by the local culture and needs.
However, because different explanatory models determine help-
seeking patterns, people in remote rural areas may find it easier to go
to traditional healers and religious centres for help than to a health
centre [76,77]. Furthermore, in many LMICs more than 90% of
people with schizophrenia live with their families who manage most
aspects of patients’ lives. Thus, efforts to increase demand for care
packages in such countries should be primarily targeted at families.
Similarly, issues such as jobs and employment are best dealt with by a
discussion between patients, families, and potential employers in
many LMICs [78]. Finally, societies in many LMICs do not believe
that overinvolvement (a behaviour marked by an exaggerated
emotional response, excessive self-sacrifice, and overprotectiveness)
with younger or ill family members is necessarily harmful. Thus, in
care packages for LMICs that include aspects of the expressed
emotion theory (the idea that negative emotions expressed by family
members can be harmful to the person with schizophrenia) [51],
baseline measures of expressed emotion must be modified to allow for
overinvolvement being routinely higher in LMICs than in Western
cultures [79] if demand for the package is to be optimised.
Interventions to Improve Access to the Package
One assumption behind establishing packages of care for use in
LMIC settings is that there is clinical validity in the concept of
schizophrenia across diverse populations [80]. Where nonspecialists
prescribe medication, it has been argued that treatment of symptoms
is more appropriate than arriving at a diagnosis [81]. In the
Tanzanian national programme, for example, ‘‘acute psychosis’’ and
‘‘chronic psychosis’’ form the basis for treatment rather than
‘‘schizophrenia’’ [81]. In this type of delivery model, treatment is
initiated in the acute phase and all new cases are reviewed within a
fixed period of time (for example, a month) if the front-line worker is
not a specialist. This type of delivery model reinforces the importance
of a system for supervision and referral but also suggests that health
workers in LMICs should be trained to deal with transient psychotic
disorders [82,83] and to identify possession states, which might be
better managed by traditional healers [84].
A common problem encountered in the treatment of schizo-
phrenia is poor compliance with treatment. This behaviour can be
due to lack of understanding of the importance of ongoing
treatment for the maintenance of good health and the prevention
of relapse or a lack of willingness on the part of the client to take
their drugs because of unpleasant side effects. Some patients may
refuse to take their drugs because they do not believe they require
treatment at all. In other cases, poverty may prevent patients
buying drugs or travelling to a care facility. Thus, services that
emphasise ease of access, affordability, and family engagement are
necessary to overcome these barriers in LMICs [52,53,57–60].
Interventions to Manage Serious or Complex Cases
Around 40%–50% of patients with schizophrenia disorders are
known to have made at least one suicide attempt and 10% of them
complete suicide. A recent study in a HIC found a lifetime suicide
prevalence of 4.5%–5.0% for patients with schizophrenia disorder
[85]. Despite the new medications, there is little evidence for
decreasing rates of suicide among people with schizophrenia [6].
Other evidence, mostly from HICs, indicates that high rates of
suicide are associated with drug/alcohol use, severity of symptoms,
positive symptoms, first episode psychosis, being a young male,
longer duration of untreated psychosis, younger age at the onset of
psychosis, recent discharge from hospital, unemployment, hope-
lessness, high levels of premorbid functioning, high levels of
cognitive functions, absence of supportive environment, poor
adherence to treatment, and a family history of suicidal attempts
[6,86]. Mental-health workers in LMICs need to be carefully
trained to screen and deal with suicidal thoughts and behaviour
among patients with schizophrenia [87–89].
Interventions to Manage Impacts on Social Outcomes
People with schizophrenia are more liable to commit crimes than
the general population [90–92]. The onset of a psychotic episode in
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an LMIC is more likely to be linked to episodes of assaultive
behaviour or contact with police than in a HIC [93,94].
Furthermore, violent behaviour is seen more frequently in patients
with active delusions and hallucinations where there is comorbidity
with substance abuse, and in younger persons [90]. Because actual
or threatened violent behaviour is a recognised major stimulus for
seeking care, mental-health workers in LMICs need to be trained to
manage aggressive behaviour, and prison staff should be able to
refer patients whose altered behaviour may be due to mental illness.
Packages of Care for Schizophrenia in LMICs
Our review suggests that recovery in schizophrenia in LMICs
can be achieved by using antipsychotics, along with psychosocial
education and/or family interventions. The adjunctive use of
psychosocial educational strategies can help to improve knowledge
and awareness of the condition, lower stigma, and improve
understanding of the role of medicines and the importance of
compliance to treatment for prevention of relapse. People with
schizophrenia may also need support for housing and employ-
ment. Although there are few organizations that advocate and
defend human rights in LMICs, they can nevertheless actively
lobby for better mental-health services. Models for supporting
persons with disabilities that emphasise a broad, empowerment-
and rights-based approach such as community-based rehabilita-
tion [31,32] are also applicable to people with mental illness in
LMICs. Table 3 proposes a package of care for schizophrenia in
LMICs that incorporates these aspects of care and contrasts this
package with one that can be provided in HICs.
At present, more than a third of patients in LMICs with chronic
schizophrenia remain untreated, even when psychiatric services
are available [95]. Although both social and clinical factors seem
Table 2. Delivering schizophrenia treatments.
Step How By Whom
In What
Settings
Increasing demand
for the package
Improve mental health literacy in the community [74] Community-based service staff; community volunteers/
extension workers linked to primary health care services,
in collaboration with governmental and relevant NGOs
Community
Key informant identification of cases, direct social contact
with people with mental illness at the individual level [32,75]
— —
Community education about causes, treatability, and how
to access services [75]
— —
Social marketing at the population level [75] — —
Increasing access
to the package
Use local primary health care services and/or general
hospitals to deliver the package [70–72]
Service providers, governments, insurance providers and
users
Community
Increase acceptability of service by involving service users
and community members, establish self-help groups [32]
— —
Improving recognition
of the disorder
Train local/traditional practitioners to recognize and refer
(key informants)
Local specialists in government/NGO, using international
guidelines
Primary care
Train and supervise community health workers to deliver
psycho-education [32,54,59,60]
— —
Establish practical protocols/operationalised checklists to
improve diagnostic reliability
— —
Initiation of evidence
based treatments
Train general physicians and primary health care workers
to use antipsychotics [101–103]
Local specialists using training materials for medical and
psychosocial interventions
Primary care
Train general physicians and primary health care workers
to identify the main side effects of medication (Parkinsonism,
akathisia, dystonia, and tardive dyskinesa) [101–103]
— —
Train and supervise primary health care workers to deliver
psycho-educational intervention [54,57,58]
— —
Managing serious or
complex cases
Train general physicians and primary health care workers
to deal with agitation and dangerous behaviour [46,47]
Training and supervision by local specialists in
government/NGO
Primary care
Train general physicians and primary health care workers to
recognize and treat refractory patients with clozapine [39,101]
— —
Achieving optimal
outcomes
Train general physicians and primary health care workers
to maintain follow-up with physical routine examinations,
assessment of compliance [59,60], and screen for suicidal
thoughts [87–89]
Training and supervision by local specialists in
government/NGO
Primary care
Addressing impacts
on other health/social
outcomes
Occupation/livelihoods support through access to capital,
skills training, inclusive education [32]
User and carer organizations, NGOs, government and
alliances, criminal justice system, and interested
stakeholders and community members
Community
Human rights protection, prisoners’ health care, access to
justice in cases of abuse
— —
Advocacy for appropriate, rights-based legislation, and
social protection [32]
— —
NGO, nongovernmental organisation.
doi:10.1371/journal.pmed.1000165.t002
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to contribute to this treatment gap, explanatory models of mental
illness held by rural people in many of the countries will need to be
explored and addressed if this gap is to be reduced [96]. These
explanatory models are often rooted in local cultural and religious
beliefs and values, which underscores the need for any community
care program to consider these factors while planning interven-
tions. Furthermore, because early detection leads to better
outcomes in schizophrenia [15,16], emphasis should be placed
on increasing demand for the package, increasing access to the
package, and increasing recognition of the disorder (see Table 2).
A recent study conducted in Chile, Nigeria, and Sri Lanka
(LMICs that are representative of South America, Africa, and
Southeast Asia, respectively) showed that in these countries FGAs
constitute a better value choice than SGAs because they are
cheaper and more cost-effective [97]. However, as indicated in
Table 3, SGAs should be considered in countries where they have
a similar cost to FGAs because of the lower incidence of
extrapyramidal side effects with these drugs [43,44]. Importantly,
other studies done in LMICs indicate that the combination of
pharmacotherapy and psycho-educational interventions is more
cost-effective than the use of drugs alone [97–99].
As shown in Table 3, specialist services for particular groups
such as cognitive behaviour therapy or assertive outreach services
should be reserved for high resource settings [100]. Furthermore,
although inpatient beds are a necessary component of a
comprehensive package of care—particularly for the treatment
of severe, acute episodes of psychosis—these beds should be
available in the mental-health wards of general hospitals in LMICs
rather than solely in specialist hospitals [100]. Admissions in this
environment are generally more locally accessible, more afford-
able, and less stigmatising. These general hospital psychiatry
departments can also provide direct supervision and secondary
referral services to local practitioners, whereas tertiary-level
specialist hospitals can focus more on training, research, and
advocacy for improved national systems for delivery of mental-
health care.
In summary, in LMICs general physicians and primary health
care workers can be trained to recognise and treat people with
psychotic disorders in the community. A package of care that
combines low doses of conventional antipsychotics along with
brief, simple psycho-educational interventions is recommended as
an important strategy to decrease the treatment gap for
schizophrenia in LMICs. In our view, the treatment package
presented here, if combined with a scale-up of mental-health
services in LMICs [72], should provide both a feasible and a cost-
effective way to extend treatment to many more patients with
schizophrenia who live in LMICs, and should have a major
positive impact upon their lives and upon the lives of their families.
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